This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
ANURUDDHA A. H. M. P.
University of Colombo
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The use of growth factors and stem cells as the core treating agents is one step into creating a biocompatible Solid Lipid Nano Particles (SLNP) for treatments. Apart from obtaining these growth factors and stem cells from the patients, using the bi-product of the extraction process which is the lipid of the patient for the production of the SLNP assures the final product to be biocompatible and of a unique structure. The use of autologous cells and proteins from the patients makes the entire process medically ethical and more viable for treatment procedures. This article, thus discusses on the experimental process of developing such SLNP and the introduction of the relevant medical contraption designed uniquely for the procedure inclusive of a specified membrane.
Keywords
growth factors, stem cells, core treating agents, Solid Lipid Nano Particles (SLNP)
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 11 Mar, 2021
No community comments so far
Review #1 received
Received 02 Apr, 2021
Review #2 received
Received 02 Apr, 2021
Reviewer #4 agreed
On 30 Mar, 2021
Reviewer #3 agreed
On 30 Mar, 2021
Reviewer #2 agreed
On 30 Mar, 2021
Reviewer #5 agreed
On 30 Mar, 2021
Reviewer #1 agreed
On 30 Mar, 2021
Reviewers invited
Invitations sent on 15 Mar, 2021
Editor assigned
On 15 Mar, 2021
Editor invited
On 08 Mar, 2021
Submission checks complete
On 08 Mar, 2021
First submitted
On 25 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Stem Cell & Developmental Cell Biology
Learn more about our company.
This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
ANURUDDHA A. H. M. P.
University of Colombo
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 11 Mar, 2021
No community comments so far
Review #1 received
Received 02 Apr, 2021
Review #2 received
Received 02 Apr, 2021
Reviewer #4 agreed
On 30 Mar, 2021
Reviewer #3 agreed
On 30 Mar, 2021
Reviewer #2 agreed
On 30 Mar, 2021
Reviewer #5 agreed
On 30 Mar, 2021
Reviewer #1 agreed
On 30 Mar, 2021
Reviewers invited
Invitations sent on 15 Mar, 2021
Editor assigned
On 15 Mar, 2021
Editor invited
On 08 Mar, 2021
Submission checks complete
On 08 Mar, 2021
First submitted
On 25 Feb, 2021
Subject Areas
Stem Cell & Developmental Cell Biology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The use of growth factors and stem cells as the core treating agents is one step into creating a biocompatible Solid Lipid Nano Particles (SLNP) for treatments. Apart from obtaining these growth factors and stem cells from the patients, using the bi-product of the extraction process which is the lipid of the patient for the production of the SLNP assures the final product to be biocompatible and of a unique structure. The use of autologous cells and proteins from the patients makes the entire process medically ethical and more viable for treatment procedures. This article, thus discusses on the experimental process of developing such SLNP and the introduction of the relevant medical contraption designed uniquely for the procedure inclusive of a specified membrane.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Loading...